Stem cell transplants offer long-term benefits for pediatric cancer patients receiving immunotherapy
Apr 1 2021
Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds.
Daniel Trey Lee is conducting pioneering clinical research in the battle against childhood cancer. Image Credit: UVA Health
The research, with an average follow up of nearly five years, suggests that stem cell transplants offer long-term benefits for young patients who receive the cutting-edge immunotherapy. CAR T-cell therapy results in complete remission in 60%-100% of patients initially, but the relapse rate is high. However, among those who received a stem cell transplant after CARs, the relapse rate was less than 10% two years later.
Ajinomoto and Bright Peak partner to develop immunocytokines Ajinomoto Co., Inc, and Bright Peak Therapeutics Inc. have entered into a research collaboration and license agreement to develop immunocytokines.
Basel, Switzerland based, Bright Peak, is a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease. The deal sees it incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the development of Bright Peak immunocytokines.
The companies outlined that there is potential for the combination of antibodies with Bright Peak s cytokine derivatives conjugated by AJICAP to target wide range of oncology applications, the technology may be harnessed to provide a clinical benefit to patients.
Date Time
Share
A leap forward in research on CAR T cell therapy – Cellular engineering makes it possible to target therapy also against solid
A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumours in addition to leukaemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future.
In cancer immunotherapy, cells in the patient’s own immune system are activated to attack cancer cells. CAR T cell therapy has been one of the most significant recent advances in immunotherapies targeted at cancer.
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy.
DREAM3R will determine if concurrent chemo-immunotherapy can improve outcomes in malignant pleural mesothelioma, especially for the majority of patients with the epithelioid subtype. Both the DREAM and PrE0505 phase 2 trials showed remarkable results in MPM with the combination of chemotherapy and durvalumab, and warrant confirmation in a randomized phase 3 trial.